To determine the feasibility of whether the addition of key prebiotics administered orally can mitigate some of the most problematic side-effects of the most common psychiatric medications - weight gain and metabolic abnormalities caused by some antidepressants, mood stabilizers and antipsychotics. In the initial part of the study, we aim to determine feasibility of the study and evaluate participant compliance. Our clinical trial will encourage the growth of Akkermansia muciniphila (AM) through enteric-coated orally-administered acetate (apple cider vinegar powder in capsules) in 16-to-28 year-old patients who have already experienced weight gain while on stable doses of psychiatric medication, with the hypothesis that the addition of this prebiotic will result in alterations in gut microbiota and measurable weight loss, as well as improvement in metabolic measurements. Primary Objective: * To evaluate feasibility of using acetate in a large-scale clinical trial, including considerations for protocol, study agent, recruitment, retention, adverse events, budget, staff, facility, and patient experience * To estimate effect size of change in AM relative abundance by measuring pre- and post-intervention levels for use in designing future large-scale clinical trials Secondary Objectives: * To determine whether acetate administered orally shows an observable effect on weight gain as a side effect from antidepressants, mood stabilizers, and/or antipsychotics in a sample of participants already on stable doses of at least one of these medications * To determine changes in metabolic syndrome profile, as indicated by blood pressure and high-density lipoprotein. * To conduct preliminary analyses on any possible changes in mood/anxiety symptoms pre- versus post-intervention * To identify and define other potential confounders or effect modifiers of our primary and secondary objectives that should be considered in future study designs
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
10
Consumer-grade apple cider vinegar (ACV) capsules will have extra enteric coating applied for delivery further into the GI tract.
First Episode Mood and Anxiety Disorders Program (FEMAP)
London, Ontario, Canada
RECRUITINGFeasibility: Recruitment success
Number of potential participants approached to number expressing interest, and number invited to number recruited (recruitment success)
Time frame: 5 months
Feasibility: Retention
Number recruited to number retained (attrition)
Time frame: 5 months
Feasibility: Adherence
Number adhering to intervention protocol quantified through number of capsules returned at end of trial
Time frame: 5 months
Feasibility: Adverse Events
A study-specific data form for collecting adverse events
Time frame: 5 months
Akkermansia Muciniphila abundance
Relative abundance (proportion) of AM in stool at inception compared to all other species identified, and change in relative abundance from pre- to post-intervention
Time frame: 5 months
Body Weight
Standard Medical-grade floor scale
Time frame: 5 months, recorded monthly
Metabolic Indicator: Blood pressure
Blood pressure using medical-grade arm cuff (mm/Hg, Systolic and Diastolic)
Time frame: 5 months
Metabolic Indicator: High-Density Lipoproteins
HDL cholesterol assayed from antecubital blood draw, expressed in mg/dL
Time frame: 5 months
Mood: Depression
Quick Inventory of Depressive Symptomatology (QIDS-SR, Rush et al. 2003) - baseline scores to describe the sample, change from pre-post intervention to explore potential treatment effect
Time frame: 5 months, captured monthly
Mood: Anxiety
Overall Anxiety Severity and Impairment Scale (OASIS, Barlow et al. 2010) - baseline scores to describe the sample, change from pre-post intervention to explore potential treatment effect
Time frame: 5 months, captured monthly
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.